APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Antibodies (rAbs)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Recombinant Antibodies (rAbs) Industry Research Report 2026

19 December 2025150 pages

Choose your research edition.

Industry ResearchRecombinant Antibodies (rAbs) Industry Research Report 2026150 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Antibodies (rAbs) Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Recombinant Antibodies (rAbs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Antibodies (rAbs) Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Antibodies (rAbs) Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Recombinant Antibodies (rAbs) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Recombinant Antibodies (rAbs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Recombinant Antibodies (rAbs) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Recombinant Antibodies (rAbs) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Recombinant Antibodies (rAbs) include Abcam, Abeomics, Abnova Corporation, Absolute Antibody, Activity Signaling, AIVD Biotech, Bio X Cell, BioLegend and Bio-Rad, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Recombinant Antibodies (rAbs) market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Recombinant Antibodies (rAbs) Market by Company

Abcam

Abeomics

Abnova Corporation

Absolute Antibody

Activity Signaling

AIVD Biotech

Bio X Cell

BioLegend

Bio-Rad

Bon Opus Biosciences

Creative Biolabs

Creative Diagnostics

Enzo Life Sciences, Inc.

GRP GmbH

HUABIO

Miltenyi Biotec

NSJ Bioreagents

PROGEN

RevMab Biosciences USA, Inc.

Signalway Antibody LLC

Recombinant Antibodies (rAbs) Segment by Type

Goat

Mouse

Rabbit

Others

Recombinant Antibodies (rAbs) Segment by Application

Pharmaceutical & Biotechnology

Hospitals & Diagnostic Laboratories

Research Institutes

Others

Recombinant Antibodies (rAbs) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Antibodies (rAbs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Antibodies (rAbs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Antibodies (rAbs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Recombinant Antibodies (rAbs) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Recombinant Antibodies (rAbs) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Recombinant Antibodies (rAbs) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Recombinant Antibodies (rAbs) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Recombinant Antibodies (rAbs) Sales (L) of Manufacturers (2021-2026) Table 7. Global Recombinant Antibodies (rAbs) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Recombinant Antibodies (rAbs) Revenue of Manufacturers (2021-2026) Table 9. Global Recombinant Antibodies (rAbs) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Recombinant Antibodies (rAbs) Average Price (US$/L) of Manufacturers (2021-2026) Table 11. Global Recombinant Antibodies (rAbs) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Recombinant Antibodies (rAbs), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Recombinant Antibodies (rAbs), Product Type & Application Table 14. Global Recombinant Antibodies (rAbs) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Recombinant Antibodies (rAbs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abcam Company Information Table 19. Abcam Business Overview Table 20. Abcam Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 21. Abcam Recombinant Antibodies (rAbs) Product Portfolio Table 22. Abcam Recent Developments Table 23. Abeomics Company Information Table 24. Abeomics Business Overview Table 25. Abeomics Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 26. Abeomics Recombinant Antibodies (rAbs) Product Portfolio Table 27. Abeomics Recent Developments Table 28. Abnova Corporation Company Information Table 29. Abnova Corporation Business Overview Table 30. Abnova Corporation Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 31. Abnova Corporation Recombinant Antibodies (rAbs) Product Portfolio Table 32. Abnova Corporation Recent Developments Table 33. Absolute Antibody Company Information Table 34. Absolute Antibody Business Overview Table 35. Absolute Antibody Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 36. Absolute Antibody Recombinant Antibodies (rAbs) Product Portfolio Table 37. Absolute Antibody Recent Developments Table 38. Activity Signaling Company Information Table 39. Activity Signaling Business Overview Table 40. Activity Signaling Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 41. Activity Signaling Recombinant Antibodies (rAbs) Product Portfolio Table 42. Activity Signaling Recent Developments Table 43. AIVD Biotech Company Information Table 44. AIVD Biotech Business Overview Table 45. AIVD Biotech Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 46. AIVD Biotech Recombinant Antibodies (rAbs) Product Portfolio Table 47. AIVD Biotech Recent Developments Table 48. Bio X Cell Company Information Table 49. Bio X Cell Business Overview Table 50. Bio X Cell Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 51. Bio X Cell Recombinant Antibodies (rAbs) Product Portfolio Table 52. Bio X Cell Recent Developments Table 53. BioLegend Company Information Table 54. BioLegend Business Overview Table 55. BioLegend Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 56. BioLegend Recombinant Antibodies (rAbs) Product Portfolio Table 57. BioLegend Recent Developments Table 58. Bio-Rad Company Information Table 59. Bio-Rad Business Overview Table 60. Bio-Rad Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 61. Bio-Rad Recombinant Antibodies (rAbs) Product Portfolio Table 62. Bio-Rad Recent Developments Table 63. Bon Opus Biosciences Company Information Table 64. Bon Opus Biosciences Business Overview Table 65. Bon Opus Biosciences Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 66. Bon Opus Biosciences Recombinant Antibodies (rAbs) Product Portfolio Table 67. Bon Opus Biosciences Recent Developments Table 68. Creative Biolabs Company Information Table 69. Creative Biolabs Business Overview Table 70. Creative Biolabs Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 71. Creative Biolabs Recombinant Antibodies (rAbs) Product Portfolio Table 72. Creative Biolabs Recent Developments Table 73. Creative Diagnostics Company Information Table 74. Creative Diagnostics Business Overview Table 75. Creative Diagnostics Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 76. Creative Diagnostics Recombinant Antibodies (rAbs) Product Portfolio Table 77. Creative Diagnostics Recent Developments Table 78. Enzo Life Sciences, Inc. Company Information Table 79. Enzo Life Sciences, Inc. Business Overview Table 80. Enzo Life Sciences, Inc. Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 81. Enzo Life Sciences, Inc. Recombinant Antibodies (rAbs) Product Portfolio Table 82. Enzo Life Sciences, Inc. Recent Developments Table 83. GRP GmbH Company Information Table 84. GRP GmbH Business Overview Table 85. GRP GmbH Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 86. GRP GmbH Recombinant Antibodies (rAbs) Product Portfolio Table 87. GRP GmbH Recent Developments Table 88. HUABIO Company Information Table 89. HUABIO Business Overview Table 90. HUABIO Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 91. HUABIO Recombinant Antibodies (rAbs) Product Portfolio Table 92. HUABIO Recent Developments Table 93. Miltenyi Biotec Company Information Table 94. Miltenyi Biotec Business Overview Table 95. Miltenyi Biotec Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 96. Miltenyi Biotec Recombinant Antibodies (rAbs) Product Portfolio Table 97. Miltenyi Biotec Recent Developments Table 98. NSJ Bioreagents Company Information Table 99. NSJ Bioreagents Business Overview Table 100. NSJ Bioreagents Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 101. NSJ Bioreagents Recombinant Antibodies (rAbs) Product Portfolio Table 102. NSJ Bioreagents Recent Developments Table 103. PROGEN Company Information Table 104. PROGEN Business Overview Table 105. PROGEN Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 106. PROGEN Recombinant Antibodies (rAbs) Product Portfolio Table 107. PROGEN Recent Developments Table 108. RevMab Biosciences USA, Inc. Company Information Table 109. RevMab Biosciences USA, Inc. Business Overview Table 110. RevMab Biosciences USA, Inc. Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 111. RevMab Biosciences USA, Inc. Recombinant Antibodies (rAbs) Product Portfolio Table 112. RevMab Biosciences USA, Inc. Recent Developments Table 113. Signalway Antibody LLC Company Information Table 114. Signalway Antibody LLC Business Overview Table 115. Signalway Antibody LLC Recombinant Antibodies (rAbs) Sales (L), Revenue (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 116. Signalway Antibody LLC Recombinant Antibodies (rAbs) Product Portfolio Table 117. Signalway Antibody LLC Recent Developments Table 118. Global Recombinant Antibodies (rAbs) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Recombinant Antibodies (rAbs) Sales by Region (2021-2026) & (L) Table 120. Global Recombinant Antibodies (rAbs) Sales Market Share by Region (2021-2026) Table 121. Global Recombinant Antibodies (rAbs) Sales by Region (2027-2032) & (L) Table 122. Global Recombinant Antibodies (rAbs) Sales Market Share by Region (2027-2032) Table 123. Global Recombinant Antibodies (rAbs) Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Recombinant Antibodies (rAbs) Revenue Market Share by Region (2021-2026) Table 125. Global Recombinant Antibodies (rAbs) Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Recombinant Antibodies (rAbs) Revenue Market Share by Region (2027-2032) Table 127. North America Recombinant Antibodies (rAbs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Recombinant Antibodies (rAbs) Sales by Country (2021-2026) & (L) Table 129. North America Recombinant Antibodies (rAbs) Sales by Country (2027-2032) & (L) Table 130. North America Recombinant Antibodies (rAbs) Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Recombinant Antibodies (rAbs) Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Recombinant Antibodies (rAbs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Recombinant Antibodies (rAbs) Sales by Country (2021-2026) & (L) Table 134. Europe Recombinant Antibodies (rAbs) Sales by Country (2027-2032) & (L) Table 135. Europe Recombinant Antibodies (rAbs) Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Recombinant Antibodies (rAbs) Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Recombinant Antibodies (rAbs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Recombinant Antibodies (rAbs) Sales by Country (2021-2026) & (L) Table 139. Asia Pacific Recombinant Antibodies (rAbs) Sales by Country (2027-2032) & (L) Table 140. Asia Pacific Recombinant Antibodies (rAbs) Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Recombinant Antibodies (rAbs) Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Recombinant Antibodies (rAbs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Recombinant Antibodies (rAbs) Sales by Country (2021-2026) & (L) Table 144. South America Recombinant Antibodies (rAbs) Sales by Country (2027-2032) & (L) Table 145. South America Recombinant Antibodies (rAbs) Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Recombinant Antibodies (rAbs) Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Recombinant Antibodies (rAbs) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Recombinant Antibodies (rAbs) Sales by Country (2021-2026) & (L) Table 149. Middle East and Africa Recombinant Antibodies (rAbs) Sales by Country (2027-2032) & (L) Table 150. Middle East and Africa Recombinant Antibodies (rAbs) Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Recombinant Antibodies (rAbs) Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Recombinant Antibodies (rAbs) Sales by Type (2021-2026) & (L) Table 153. Global Recombinant Antibodies (rAbs) Sales by Type (2027-2032) & (L) Table 154. Global Recombinant Antibodies (rAbs) Sales Market Share by Type (2021-2026) Table 155. Global Recombinant Antibodies (rAbs) Sales Market Share by Type (2027-2032) Table 156. Global Recombinant Antibodies (rAbs) Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Recombinant Antibodies (rAbs) Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Recombinant Antibodies (rAbs) Revenue Market Share by Type (2021-2026) Table 159. Global Recombinant Antibodies (rAbs) Revenue Market Share by Type (2027-2032) Table 160. Global Recombinant Antibodies (rAbs) Price by Type (2021-2026) & (US$/L) Table 161. Global Recombinant Antibodies (rAbs) Price by Type (2027-2032) & (US$/L) Table 162. Global Recombinant Antibodies (rAbs) Sales by Application (2021-2026) & (L) Table 163. Global Recombinant Antibodies (rAbs) Sales by Application (2027-2032) & (L) Table 164. Global Recombinant Antibodies (rAbs) Sales Market Share by Application (2021-2026) Table 165. Global Recombinant Antibodies (rAbs) Sales Market Share by Application (2027-2032) Table 166. Global Recombinant Antibodies (rAbs) Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Recombinant Antibodies (rAbs) Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Recombinant Antibodies (rAbs) Revenue Market Share by Application (2021-2026) Table 169. Global Recombinant Antibodies (rAbs) Revenue Market Share by Application (2027-2032) Table 170. Global Recombinant Antibodies (rAbs) Price by Application (2021-2026) & (US$/L) Table 171. Global Recombinant Antibodies (rAbs) Price by Application (2027-2032) & (US$/L) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Recombinant Antibodies (rAbs) Distributors List Table 175. Recombinant Antibodies (rAbs) Customers List Table 176. Recombinant Antibodies (rAbs) Industry Trends Table 177. Recombinant Antibodies (rAbs) Industry Drivers Table 178. Recombinant Antibodies (rAbs) Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Recombinant Antibodies (rAbs) Product Image Figure 5. Global Recombinant Antibodies (rAbs) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Recombinant Antibodies (rAbs) Market Size (2021-2032) & (US$ Million) Figure 7. Global Recombinant Antibodies (rAbs) Sales (2021-2032) & (L) Figure 8. Global Recombinant Antibodies (rAbs) Average Price (US$/L) & (2021-2032) Figure 9. Goat Product Image Figure 10. Mouse Product Image Figure 11. Rabbit Product Image Figure 12. Others Product Image Figure 13. Pharmaceutical & Biotechnology Product Image Figure 14. Hospitals & Diagnostic Laboratories Product Image Figure 15. Research Institutes Product Image Figure 16. Others Product Image Figure 17. Global Recombinant Antibodies (rAbs) Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Recombinant Antibodies (rAbs), Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Recombinant Antibodies (rAbs) Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Recombinant Antibodies (rAbs) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Recombinant Antibodies (rAbs) Sales by Region in 2025 Figure 23. Global Recombinant Antibodies (rAbs) Revenue by Region in 2025 Figure 24. North America Recombinant Antibodies (rAbs) Market Size by Country in 2025 Figure 25. North America Recombinant Antibodies (rAbs) Sales Market Share by Country (2021-2032) Figure 26. North America Recombinant Antibodies (rAbs) Revenue Market Share by Country (2021-2032) Figure 27. United States Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Recombinant Antibodies (rAbs) Market Size by Country in 2025 Figure 30. Europe Recombinant Antibodies (rAbs) Sales Market Share by Country (2021-2032) Figure 31. Europe Recombinant Antibodies (rAbs) Revenue Market Share by Country (2021-2032) Figure 32. Germany Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Recombinant Antibodies (rAbs) Market Size by Country in 2025 Figure 38. Asia Pacific Recombinant Antibodies (rAbs) Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Recombinant Antibodies (rAbs) Revenue Market Share by Country (2021-2032) Figure 40. China Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Recombinant Antibodies (rAbs) Market Size by Country in 2025 Figure 49. South America Recombinant Antibodies (rAbs) Sales Market Share by Country (2021-2032) Figure 50. South America Recombinant Antibodies (rAbs) Revenue Market Share by Country (2021-2032) Figure 51. Mexico Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Middle East and Africa Recombinant Antibodies (rAbs) Market Size by Country in 2025 Figure 55. Middle East and Africa Recombinant Antibodies (rAbs) Sales Market Share by Country (2021-2032) Figure 56. Middle East and Africa Recombinant Antibodies (rAbs) Revenue Market Share by Country (2021-2032) Figure 57. Turkey Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. UAE Recombinant Antibodies (rAbs) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Global Recombinant Antibodies (rAbs) Sales Market Share by Type (2021-2032) Figure 61. Global Recombinant Antibodies (rAbs) Revenue Market Share by Type (2021-2032) Figure 62. Global Recombinant Antibodies (rAbs) Price (US$/L) by Type (2021-2032) Figure 63. Global Recombinant Antibodies (rAbs) Sales Market Share by Application (2021-2032) Figure 64. Global Recombinant Antibodies (rAbs) Revenue Market Share by Application (2021-2032) Figure 65. Global Recombinant Antibodies (rAbs) Price (US$/L) by Application (2021-2032) Figure 66. Recombinant Antibodies (rAbs) Value Chain Figure 67. Recombinant Antibodies (rAbs) Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Recombinant Antibodies (rAbs) Industry Opportunities and Challenges

Scope & coverage.

Types
  • Goat
  • Mouse
  • Rabbit
  • Others
Applications
  • Pharmaceutical & Biotechnology
  • Hospitals & Diagnostic Laboratories
  • Research Institutes
  • Others
Companies covered
  • Abcam
  • Abeomics
  • Abnova Corporation
  • Absolute Antibody
  • Activity Signaling
  • AIVD Biotech
  • Bio X Cell
  • BioLegend
  • Bio-Rad
  • Bon Opus Biosciences
  • Creative Biolabs
  • Creative Diagnostics
  • Enzo Life Sciences, Inc.
  • GRP GmbH
  • HUABIO
  • Miltenyi Biotec
  • NSJ Bioreagents
  • PROGEN
  • RevMab Biosciences USA, Inc.
  • Signalway Antibody LLC

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Recombinant Antibodies (rAbs) Market Size (2021-2032)
  4. 2.2.2 Global Recombinant Antibodies (rAbs) Sales (2021-2032)
  5. 2.2.3 Global Recombinant Antibodies (rAbs) Market Average Price (2021-2032)
  6. 2.3 Recombinant Antibodies (rAbs) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Goat
  9. 2.3.3 Mouse
  10. 2.3.4 Rabbit
  11. 2.3.5 Others
  12. 2.4 Recombinant Antibodies (rAbs) by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Pharmaceutical & Biotechnology
  15. 2.4.3 Hospitals & Diagnostic Laboratories
  16. 2.4.4 Research Institutes
  17. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Recombinant Antibodies (rAbs) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Recombinant Antibodies (rAbs) Sales (L) of Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Antibodies (rAbs) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Antibodies (rAbs) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Recombinant Antibodies (rAbs) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Recombinant Antibodies (rAbs), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Recombinant Antibodies (rAbs), Product Type & Application
  8. 3.8 Global Manufacturers of Recombinant Antibodies (rAbs), Established Date
  9. 3.9 Global Recombinant Antibodies (rAbs) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abcam
  2. 4.1.1 Abcam Company Information
  3. 4.1.2 Abcam Business Overview
  4. 4.1.3 Abcam Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abcam Recombinant Antibodies (rAbs) Product Portfolio
  6. 4.1.5 Abcam Recent Developments
  7. 4.2 Abeomics
  8. 4.2.1 Abeomics Company Information
  9. 4.2.2 Abeomics Business Overview
  10. 4.2.3 Abeomics Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Abeomics Recombinant Antibodies (rAbs) Product Portfolio
  12. 4.2.5 Abeomics Recent Developments
  13. 4.3 Abnova Corporation
  14. 4.3.1 Abnova Corporation Company Information
  15. 4.3.2 Abnova Corporation Business Overview
  16. 4.3.3 Abnova Corporation Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Abnova Corporation Recombinant Antibodies (rAbs) Product Portfolio
  18. 4.3.5 Abnova Corporation Recent Developments
  19. 4.4 Absolute Antibody
  20. 4.4.1 Absolute Antibody Company Information
  21. 4.4.2 Absolute Antibody Business Overview
  22. 4.4.3 Absolute Antibody Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Absolute Antibody Recombinant Antibodies (rAbs) Product Portfolio
  24. 4.4.5 Absolute Antibody Recent Developments
  25. 4.5 Activity Signaling
  26. 4.5.1 Activity Signaling Company Information
  27. 4.5.2 Activity Signaling Business Overview
  28. 4.5.3 Activity Signaling Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Activity Signaling Recombinant Antibodies (rAbs) Product Portfolio
  30. 4.5.5 Activity Signaling Recent Developments
  31. 4.6 AIVD Biotech
  32. 4.6.1 AIVD Biotech Company Information
  33. 4.6.2 AIVD Biotech Business Overview
  34. 4.6.3 AIVD Biotech Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 AIVD Biotech Recombinant Antibodies (rAbs) Product Portfolio
  36. 4.6.5 AIVD Biotech Recent Developments
  37. 4.7 Bio X Cell
  38. 4.7.1 Bio X Cell Company Information
  39. 4.7.2 Bio X Cell Business Overview
  40. 4.7.3 Bio X Cell Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Bio X Cell Recombinant Antibodies (rAbs) Product Portfolio
  42. 4.7.5 Bio X Cell Recent Developments
  43. 4.8 BioLegend
  44. 4.8.1 BioLegend Company Information
  45. 4.8.2 BioLegend Business Overview
  46. 4.8.3 BioLegend Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 BioLegend Recombinant Antibodies (rAbs) Product Portfolio
  48. 4.8.5 BioLegend Recent Developments
  49. 4.9 Bio-Rad
  50. 4.9.1 Bio-Rad Company Information
  51. 4.9.2 Bio-Rad Business Overview
  52. 4.9.3 Bio-Rad Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Bio-Rad Recombinant Antibodies (rAbs) Product Portfolio
  54. 4.9.5 Bio-Rad Recent Developments
  55. 4.10 Bon Opus Biosciences
  56. 4.10.1 Bon Opus Biosciences Company Information
  57. 4.10.2 Bon Opus Biosciences Business Overview
  58. 4.10.3 Bon Opus Biosciences Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Bon Opus Biosciences Recombinant Antibodies (rAbs) Product Portfolio
  60. 4.10.5 Bon Opus Biosciences Recent Developments
  61. 4.11 Creative Biolabs
  62. 4.11.1 Creative Biolabs Company Information
  63. 4.11.2 Creative Biolabs Business Overview
  64. 4.11.3 Creative Biolabs Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Creative Biolabs Recombinant Antibodies (rAbs) Product Portfolio
  66. 4.11.5 Creative Biolabs Recent Developments
  67. 4.12 Creative Diagnostics
  68. 4.12.1 Creative Diagnostics Company Information
  69. 4.12.2 Creative Diagnostics Business Overview
  70. 4.12.3 Creative Diagnostics Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Creative Diagnostics Recombinant Antibodies (rAbs) Product Portfolio
  72. 4.12.5 Creative Diagnostics Recent Developments
  73. 4.13 Enzo Life Sciences, Inc.
  74. 4.13.1 Enzo Life Sciences, Inc. Company Information
  75. 4.13.2 Enzo Life Sciences, Inc. Business Overview
  76. 4.13.3 Enzo Life Sciences, Inc. Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Enzo Life Sciences, Inc. Recombinant Antibodies (rAbs) Product Portfolio
  78. 4.13.5 Enzo Life Sciences, Inc. Recent Developments
  79. 4.14 GRP GmbH
  80. 4.14.1 GRP GmbH Company Information
  81. 4.14.2 GRP GmbH Business Overview
  82. 4.14.3 GRP GmbH Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 GRP GmbH Recombinant Antibodies (rAbs) Product Portfolio
  84. 4.14.5 GRP GmbH Recent Developments
  85. 4.15 HUABIO
  86. 4.15.1 HUABIO Company Information
  87. 4.15.2 HUABIO Business Overview
  88. 4.15.3 HUABIO Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 HUABIO Recombinant Antibodies (rAbs) Product Portfolio
  90. 4.15.5 HUABIO Recent Developments
  91. 4.16 Miltenyi Biotec
  92. 4.16.1 Miltenyi Biotec Company Information
  93. 4.16.2 Miltenyi Biotec Business Overview
  94. 4.16.3 Miltenyi Biotec Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Miltenyi Biotec Recombinant Antibodies (rAbs) Product Portfolio
  96. 4.16.5 Miltenyi Biotec Recent Developments
  97. 4.17 NSJ Bioreagents
  98. 4.17.1 NSJ Bioreagents Company Information
  99. 4.17.2 NSJ Bioreagents Business Overview
  100. 4.17.3 NSJ Bioreagents Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 NSJ Bioreagents Recombinant Antibodies (rAbs) Product Portfolio
  102. 4.17.5 NSJ Bioreagents Recent Developments
  103. 4.18 PROGEN
  104. 4.18.1 PROGEN Company Information
  105. 4.18.2 PROGEN Business Overview
  106. 4.18.3 PROGEN Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 PROGEN Recombinant Antibodies (rAbs) Product Portfolio
  108. 4.18.5 PROGEN Recent Developments
  109. 4.19 RevMab Biosciences USA, Inc.
  110. 4.19.1 RevMab Biosciences USA, Inc. Company Information
  111. 4.19.2 RevMab Biosciences USA, Inc. Business Overview
  112. 4.19.3 RevMab Biosciences USA, Inc. Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 RevMab Biosciences USA, Inc. Recombinant Antibodies (rAbs) Product Portfolio
  114. 4.19.5 RevMab Biosciences USA, Inc. Recent Developments
  115. 4.20 Signalway Antibody LLC
  116. 4.20.1 Signalway Antibody LLC Company Information
  117. 4.20.2 Signalway Antibody LLC Business Overview
  118. 4.20.3 Signalway Antibody LLC Recombinant Antibodies (rAbs) Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Signalway Antibody LLC Recombinant Antibodies (rAbs) Product Portfolio
  120. 4.20.5 Signalway Antibody LLC Recent Developments
5 Global Recombinant Antibodies (rAbs) Market Scenario by Region
  1. 5.1 Global Recombinant Antibodies (rAbs) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Recombinant Antibodies (rAbs) Sales by Region: 2021-2032
  3. 5.2.1 Global Recombinant Antibodies (rAbs) Sales by Region: 2021-2026
  4. 5.2.2 Global Recombinant Antibodies (rAbs) Sales by Region: 2027-2032
  5. 5.3 Global Recombinant Antibodies (rAbs) Revenue by Region: 2021-2032
  6. 5.3.1 Global Recombinant Antibodies (rAbs) Revenue by Region: 2021-2026
  7. 5.3.2 Global Recombinant Antibodies (rAbs) Revenue by Region: 2027-2032
  8. 5.4 North America Recombinant Antibodies (rAbs) Market Facts & Figures by Country
  9. 5.4.1 North America Recombinant Antibodies (rAbs) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Recombinant Antibodies (rAbs) Sales by Country (2021-2032)
  11. 5.4.3 North America Recombinant Antibodies (rAbs) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Recombinant Antibodies (rAbs) Market Facts & Figures by Country
  15. 5.5.1 Europe Recombinant Antibodies (rAbs) Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Recombinant Antibodies (rAbs) Sales by Country (2021-2032)
  17. 5.5.3 Europe Recombinant Antibodies (rAbs) Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Recombinant Antibodies (rAbs) Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Recombinant Antibodies (rAbs) Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Recombinant Antibodies (rAbs) Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Recombinant Antibodies (rAbs) Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Recombinant Antibodies (rAbs) Market Facts & Figures by Country
  35. 5.7.1 South America Recombinant Antibodies (rAbs) Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Recombinant Antibodies (rAbs) Sales by Country (2021-2032)
  37. 5.7.3 South America Recombinant Antibodies (rAbs) Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Recombinant Antibodies (rAbs) Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Recombinant Antibodies (rAbs) Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Recombinant Antibodies (rAbs) Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Recombinant Antibodies (rAbs) Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Recombinant Antibodies (rAbs) Sales by Type (2021-2032)
  2. 6.1.1 Global Recombinant Antibodies (rAbs) Sales by Type (2021-2032) & (L)
  3. 6.1.2 Global Recombinant Antibodies (rAbs) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Recombinant Antibodies (rAbs) Revenue by Type (2021-2032)
  5. 6.2.1 Global Recombinant Antibodies (rAbs) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Recombinant Antibodies (rAbs) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Recombinant Antibodies (rAbs) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Recombinant Antibodies (rAbs) Sales by Application (2021-2032)
  2. 7.1.1 Global Recombinant Antibodies (rAbs) Sales by Application (2021-2032) & (L)
  3. 7.1.2 Global Recombinant Antibodies (rAbs) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Recombinant Antibodies (rAbs) Revenue by Application (2021-2032)
  5. 7.2.1 Global Recombinant Antibodies (rAbs) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Recombinant Antibodies (rAbs) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Recombinant Antibodies (rAbs) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Recombinant Antibodies (rAbs) Value Chain Analysis
  2. 8.1.1 Recombinant Antibodies (rAbs) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Recombinant Antibodies (rAbs) Production Mode & Process
  5. 8.2 Recombinant Antibodies (rAbs) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Recombinant Antibodies (rAbs) Distributors
  8. 8.2.3 Recombinant Antibodies (rAbs) Customers
9 Global Recombinant Antibodies (rAbs) Analyzing Market Dynamics
  1. 9.1 Recombinant Antibodies (rAbs) Industry Trends
  2. 9.2 Recombinant Antibodies (rAbs) Industry Drivers
  3. 9.3 Recombinant Antibodies (rAbs) Industry Opportunities and Challenges
  4. 9.4 Recombinant Antibodies (rAbs) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst